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Prostate cancer (PCA) has the highest incidence rate and is the 
second highest cause of cancer death in men in Western 
countries. It is the second most frequent malignant tumor in 
males worldwide [1-3]. With improvements in prostate-specific 
antigen (PSA) screening, diagnostic techniques and prolonged life 
expectancy, the incidence and prevalence of PCA have increased 
steadily in the last decade [4-5]. It is reported that more than 
500,000 patients per year undergo prostate biopsy in the United 
States [6]. Current guidelines support systematic sampling with 
10 to 12 biopsy cores, which has a significantly higher cancer 
detection rate than sextant biopsies [7-9]. Nevertheless, the 
conventional biopsy protocol on the one hand misses significant 
PCA in a large percentage of patients and, on the other hand, 
detects many insignificant PCAs that do not require immediate 
treatment, resulting in overdiagnosis and overtreatment [10]. The 
estimated overdetection rate for prostate biopsy ranges from 
27% to 56% [11]. Methods for detection of PCA include PSA 
screening, digital rectal examination (DRE) and diagnostic imaging 
techniques such as ultrasound (US) and magnetic resonance 
imaging (MRI). PCA is generally a stiff lesion compared with 
normal prostate tissue and can be detected on DRE. However, 
DRE is subjective and operator dependent, and its sensitivity is 
questionable for deep or small lesions [12,13]. It has limited 
accuracy for staging disease and locating the different foci [14], 
which are two factors mandatory for planning primary therapy. 
Despite the low specificity of PSA testing and the low sensitivity 
of systematic biopsy (SB), these techniques remain the standard 
of care for PCA diagnosis, mainly because of their widespread 
availability and low cost [1, 15-17]. Ultrasound is the most 
common imaging method for direct visualization of the prostate 
because it is real time, does not involve ionizing radiation and is 
low in cost. However, transrectal ultrasound (TRUS) is not highly 
sensitive or specific (40% - 50%) in the diagnosis of PCA because 
suspicious hypo-echoic areas represent cancer in only 9% - 53% of 
cases with B-mode technique [18-21]. Nearly 58% of PCAs are 
multifocal and progress along the capsule of the prostate and 
may not appear as well-defined nodules like other malignant 
tumors. Therefore, it is difficult to detect lesions accurately using 
conventional imaging technology [22]. Meanwhile, color Doppler 
and power Doppler imaging do not substantially improve the 
diagnostic accuracy [18,21]. Pathologic results obtained by TRUS-
guided SB remain the mainstay in confirming or ruling out PCA 
[21]. Prostate biopsy also allows estimation of the aggressiveness 
of PCA (Gleason score, invasion of capsule or neurovascular 
bundles) [11]. Because of the inaccuracy of TRUS and the 
limitations of SB, improved imaging for the detection, localization 
and staging of PCA is needed. As cancerous tissue in the prostate 
has a higher stiffness compared with benign tissue, an imaging 
technique able to assess tissue stiffness would be useful in the 
diagnosis of PCA. PCA tissue becomes stiffer than the surrounding 
healthy prostate tissue because of the following changes: an 
increase in cellular density and microvascularization, destruction 
of the glandular architecture [23] and triggering of wound repair. 
This process is characterized by stromal reaction [23, 24] and 
collagen deposition surrounding the cancer [25]. Deposition of 
collagen increases significantly with Gleason grade [26, 27] and is 
linked to a significant reduction in the acinar area in the PCA 
stroma. All of these changes contribute to the increased stiffness 
of tissue affected by PCA [28]. At present, two US lastography 
techniques have been developed for image the prostate in clinic 
practice: strain elastography (SE) and shear wave elastography 
(SWE). US elastography improves both prostate lesion 
characterization and PCA detection; in particular, this approach 
can be extremely useful in the detection of prostate lesions, 
disclosing lesions on the elasticity map that are not visible on 
conventional TRUS imaging (iso-echoic lesions) or other imaging 
modalities such as on the other hand, detects many insignificant 
PCAs that do not require immediate treatment, resulting in 














TRANSRECTAL STRAIN ELASTOGRAPHY 
 
Transrectal SE assesses the differences in tissue strain produced 
by freehand manual compression, with stiffer tissues having less 
strain. Transrectal SE represents the distribution of strain and 
helps differentiate benign from malignant tissue [22]. As a novel 
biomechanical technique, transrectal SE is an improvement over 
conventional ultrasonic imaging, with better diagnostic value for 
PCA. Transrectal prostate SE is based on the analysis of tissue 
deformation generated by inducing an external mechanical 
stress (slight compressions and decompressions of the tissue by 
the transrectal transducer itself). The deformation needs to be 
uniform in intensity throughout the gland [29;30]. A speckle 
comparison, before and after compression, yields a color-coded 
map of local tissue deformation or strain, called the elastogram. 
Tissue stiffness is estimated by visualizing the differences in 
strain between adjacent regions. The stiffness color scale is 
automatically distributed from the lowest to the highest strain 
found in the image plane and displayed as an overlay on the B-
mode image. Stiff tissues exhibit reduced strain, whereas soft 
tissues have higher strain (distortion). A quality index may help 
ensure appropriate frequency and applied pressure of the 
manual compressions. Recently, the guidelines and 
recommendations of the European Federation of Societies for 
Ultrasound in Medicine and Biology Guidelines [31] and the 
Japan Society of Ultrasonics in Medicine (JSUM) [32] have 
assessed the clinical use of ultrasound elastography. These 
documents are intended to form a reference and to guide 
clinical users in a practical way. The guidelines also give practical 
advice on its use and interpretation [31;33].    
 
Procedure 
No specific preparation is required for transrectal SE, which is 
conducted after a complete, high-quality TRUS examination in 
the transverse and sagittal planes. The examination includes 
measuring the prostate volume, identifying suspicious areas in 
the gland and analyzing the periprostatic space (including the 
seminal vesicles). The same transrectal probe is used for both 
conventional US and SE. Awater-filled balloon may be placed 
between the transducer and the rectal wall to improve the 
homogeneity of the deformation [34]. The patient lies in the left 
lateral position with bended knees and hip flexion or in the 
lithotomy position. 
A cover is placed on the transducer using a moderate amount of 
coupling gel, and the transducer is slowly inserted into the 
rectum. The prostate capsule, symmetry, abnormal echogenicity 
patterns, especially hypo-echoic lesions, calcification and 
boundary are observed initially on conventional US. The 
prostate volume is measured and recorded. The entire gland is 
evaluated from the apex to the base or vice versa, including the 
seminal vesicles and periprostatic tissues. Color or power 
Doppler can then be performed if required. After conventional 
imaging, SE is performed. The elastogram is displayed over the 
B-mode image in a color-coded scale. Various color-coded scales 
can be used. Most systems have an indicator (quality index) 
displayed in real time that allows the user to determine if the 
degree of compression/release is appropriate. The frequency of 
the small compressions/release should remain constant to 
generate a continuous series of images. The quality index helps 
ensure appropriate frequency and pressure of the  
compression/release. Transrectal SE images are obtained in the 
transverse plane at up to 30 frames per second. The focus 
should be placed in the far field of the region of interest (ROI). 
The ROI should cover the entire prostate gland and the 
surrounding tissues, but avoid the bladder. Semi-quantitative 
stiffness information can be derived by measuring the strain 
ratio between two ROIs (usually one considered as the reference 
normal prostate tissue and the other as the abnormal area). The 
amount of compression/release needed for most systems is less 
than 2%. With use of the quality index for the process of 
compression/release, the pressure and direction 
of manual vibration are adjusted until stable, repeatable images 
(prostatic capsule is clear, smooth and symmetrical bilaterally, 
unless there is capsular extension of the tumor), with the 
pressure indicator bar displaying good quality are obtained. 
The images and or clips are stored in the system for further 
analysis. By stepwise scanning of the prostate  from base to 
apex, strain elastography allows detection of stiff regions and 
provides stiffness comparisons between lesions and the 
adjacent prostate tissue. Several different applications of SE of 
the prostate have been reported, including (i) characterization 
of abnormal regions detected on B-mode US, color Doppler US 
and/or power Doppler US, or MRI/multiparametric (mp) MRI, 
detection of lesions not seen with any imaging technique; (ii) 



























Contrast Enhanced UltraSound 
 
Comparisons between systematic and CEUS-targeted biopsies 
have shown that the targeted approach detects more cancers 
with a lower number of biopsy cores. CEUS has also been shown 
to detect cancers with higher Gleason scores compared with the 
systematic approach, which seems to improve prostate cancer 
grading. This article will discuss the value of CEUS in the imaging 
of prostate cancer. Newly developed US contrast agents enable 
improved detection of low-volume blood flow by increasing the 
signal-to-noise ratio. [35] Therefore, US contrast agents allow 
for a more complete delineation of the neovascular anatomy by 
enhancing the signal strength from small vessels (i.e. 
neovessels). Furthermore, these agents can be used to time the 
transit of an injected bolus. Unlike radiographic contrast media, 
which diffuse into the tissue and may obscure smaller vessels, 
microbubble echo-enhancing agents are confined to the 
vascular lumen, where they persist until they dissolve. US 
contrast agents are made of gas bubbles small enough to cross 
through capillary beds. [36] They have two main important 
acoustic properties: first, they are many times more reflective 
than blood, thus improving flow detection; and second, their 
vibrations generate higher harmonics to a much greater degree 
than surrounding tissues. The half-life of contrast agents is 
dependent on bubble construction. Bubbles can be free or 
encapsulated in soft or hard shells. The duration of 
enhancement after injection may last from a few seconds to 
many minutes, depending on the bubble type. 
Bree at al. demonstrated the potential use of contrast-enhanced 
colour Doppler to enhance the diagnostic yield in a group of 17 
patients with normal greyscale transrectal US and elevated PSA 
values. Correlation of biopsy sites with colour Doppler US 
abnormalities revealed a sensitivity of 54%, a specificity of 78%, 
a positive predictive value (PPV) of 61% and a negative 
predictive value (NPV) of 72% for the detection of prostate 
cancer. Three of the cases with a positive contrast-enhanced 
biopsy site had negative transrectal US random biopsy within 
the previous year. [37] 
Frauscher et al. examined the use of contrast-enhanced colour 
Doppler US in 72 patients identified by PSA screening in a 
previous study. Using a quantitative scale to characterise the 
degree of vascularity, the technique had a sensitivity of 53%, 
specificity of 72% and PPV of 70% in distinguishing prostate 
cancer from benign lesion. [38] Previous studies reported the 
value of contrast-enhanced colour Doppler in a prospective 
study in 2305 and 380 male screening volunteers,6 and found 
that targeted biopsies based on contrastenhanced colour 
Doppler detected as many cancers as systematic biopsies, with 
less than half the number of biopsy cores. 
Bogers et al. evaluated contrast-enhanced 3D transrectal 
ultrasound imaging of the prostate vasculature with power 
Doppler. 3D power Doppler images were obtained before and 
after intravenous (IV) administration of 2.5g Levovist™ 
(Schering, Berlin). Subsequently, random and/or directed 
transrectal US (TRUS)-guided biopsies were performed. Prostate 
vasculature was judged with respect to symmetry and vessel 
distribution. Eighteen patients with a suspicion of prostate 
cancer because of either an elevated PSA (greater than 
4.0ng/ml; Tandem-R-assay) or an abnormal DRE were included 
in the study. Prostate cancer was detected in 13 patients. 
Vascular anatomy was judged abnormal in unenhanced images 
in six cases, of which five proved malignant. Enhanced images 
were considered suspicious for malignancy in 12 cases, including 
one benign and 11 malignant biopsy results. Sensitivity of 
enhanced images was 85% (specificity 80%) compared with 38% 
for unenhanced images (specificity 80%) and 77% for 
conventional greyscale TRUS (specificity 60%). Among six 
patients who showed no B mode abnormalities, vascular 
patterns were judged abnormal in four cases, of which three 
were malignant. Based on these findings they concluded that 
contrast-enhanced 3D power Doppler angiography is feasible in 
patients with suspicion of prostate cancer who are scheduled for 












Aim of the study 
Several promising imaging techniques to identify cancer lesions 
and detect various histological growth patterns of Prostate 
Cancer are under investigation [39]. Compared to benign 
prostate tissue, multifocal cancer development is associated 
with histopathological loss of benign glandular architecture, 
increased cellular density  and altered microvasculature [40;41] . 
Transrectal SE visualizes differences in prostate tissue strain 
[42]. Due to a high rate of false-positive results, especially in 
areas of former prostatitis or benign hyperplastic nodules, 
specificity to detect PC remains variable at 71.5% to 76.6% [43, 
44]. Based on the hypothesis that histo-architectural changes in 
PC development induce hemodynamic changes, perfusion based 
imaging techniques have been developed and added to current 
imaging methods to possibly improve cancer detection [45;46]. 
CEUS enables the visualization of prostate areas with abnormal 
vascularity [39]. Adding this information  to current gray scale 
and Transrectal SE imaging methods might improve the 
visualization and detection of PC. We prospectively assessed 
whether a combined approach of  transrectal SE and CEUS in a 
multiparametric setting might improve cancer visualization 
before RP. The detection rate by this multiparametric technique, 
was compared with our personal PC detection ratewith a 





Material and methods 
 
Between November 2013 and September 2016, 100 consecutive 
patients with biopsy proven PC scheduled for RP were 
prospectively examined by a single investigator using a 
multiparametric ultrasound approach. All men underwent 
prostate biopsy more than 4 weeks before examination. Patients 
showing signs of prostatitis within 4 weeks before examination 
were excluded from study. No patient received androgen 
deprivation therapy. Each patient provided informed consent. 
Patients underwent multiparametric transrectal ultrasound 
using a HI VISION™ Preirus™ ultrasound device with a V53W 
transrectal end fire probe (Hitachi Medical, Tokyo, Japan) 1 day 
before surgery. Standardized  transrectal SE was performed with 
the patient in the left lateral position. Areas of decreased 
elasticity, were considered suspicious for PC according to the 
malignancy criteria previously described by Konig et al [47]. The 
localization of each suspicious area was assigned to the 
corresponding prostate sector. A compression scale was used to 
standardize investigator movements. Imaging was saved on 
video files. The largest cancer suspicious area during transrectal 
SE was defined as the TL and used for analysis during contrast 
enhanced imaging. To assess microvessel architecture in the 
transrectal SE determined TL, 5 ml contrast agent (25 mg 
SonoVue® in 5 ml 0.9% sodium chloride) were administered via 
an antecubital vein of the right arm as a single bolus injection, 
followed by 10 ml 0.9% sodium chloride. The contrast agent 
contains microbubbles consisting of a phospholipid shell filled 
with sulfur hexafluoride gas. The low diameter (2 to 8 m) 
enables the microbubbles to pass the pulmonary circulation and 
remain intravascular for several minutes. To visualize the 
circulation of bubbles in microvessels we used a specific 
ultrasound mode with a low mechanical index of 0.14. CEUS was 
initiated when the contrast agent was injected. A video file was 
recorded to monitor perfusion behavior in the TL with time. We 
examined 3 perfusion patterns (normoperfusion, hypoperfusion 
and hyperperfusion) of the TL compared to those of adjacent 
tissue. After surgery prostatectomy specimens were color  
inked, formalin fixed and cut into 4 mm transverse whole mount 
slides. Subsequently, 4 paraffin embedded tissue sections were 
obtained from each slide and stained with hematoxylin and 
eosin according to the Stanford protocol (48). After microscopic 
examination malignant areas on whole mount slides were 
outlined and recorded for analysis. The TL previously 
documented by transrectal SE underwent detailed examination 
by a dedicated uropathologist on the corresponding whole 
mount slide. If cancer was histopathologically confirmed, the 
maximum dimension of the lesion was measured and the 
predominant Gleason pattern was recorded. We calculated the 
sensitivity, specificity, and negative and positive predictive 
values of transrectal SE to detect tumor foci by prostate sector. 
CEUS perfusion patterns were grouped as normal 
(hypoperfused) or suspicious (hyperperfused) to estimate the 
accuracy of PC detection in each defined TL. To analyze the 
frequency of PC areas in the 3 groups during CEUS we used the 
chi-square test with significance considered at p≤0.05. 
Correlation between the CEUS perfusion pattern and the 
predominant Gleason score of the TL was evaluated with the 
Mann-Whitney U test. Data from our PC detection rate with 
Standard prostate biopsy TRUS guided, obtained analyzing the 
prostate biopsy performed by a single operator from November 
2013 to September 2016, were compared with the detection 
rate of the multiparametric ultrasound approach. SPSS® version 























A total of 100 patients (mean age 64.5 ± 8.5) were prospectively 
examined with musculoskeletal ultrasound and underwent RP. 
Mean prostate specific antigen was 11.1 ±3.4 ng/ml and mean 
prostate volume was 45.4 ± 5.6 ml. A cancer suspicious palpable 
mass was assessed by digital rectal examination in 50 of 100 
patients. Mean histopathological tumor volume was 4.12 ± 2.7 
cm3 (range 0.26 to 43.5). Histopathological analysis of RP 
specimen whole mount sections showed Gleason score 3+4 and 
4+3 in 46% and 26% of cases, respectively. Complete analysis of 
prostate sectors could be accomplished in 86 of 100 patients. Of 
the patients 14 were excluded from study because whole mount 
slides could not be accurately matched with the corresponding 
imaging TL due to fixation artifacts or slide disruption. A total of 
1.032 prostate sectors (12 per patient) were assessed. PC was 
histopathologically verified in 621 sectors with the highest 
frequency in the mid gland (39%), followed by the apical region 
(31%) and prostate base (30%). PC was more frequently 
detected in dorsal (57%) than in ventral (43%) parts of the gland. 
Systematic evaluation using transrectal SE correctly identified 
cancer in all prostate sectors with overall 49% sensitivity and 
74% specificity. Sensitivity was lower in ventral areas (30% to 
35%) compared to dorsal areas (32% to 89%). It was most 
accurate at the apex of the prostate gland (89%). In each 
prostate the largest radiographic cancer suspicious area during 
transrectal SE was defined as the TL. Maximum median 
diameter of the TL measured during transrectal SE was 14.3 mm 
(range 5.1 to 43.7). The TL was subsequently monitored using 
CEUS contrast perfusion patterns. Mean examination time, 
including transrectal SE and CEUS, was 5.3 minutes (range 2 to 
15). Of 86 TLs 58 (67%) showed a suspicious perfusion pattern, 
31 (36%) showed hypoperfusion and 27 (31%) showed 
hyperperfused tissue. Normoperfusion was found in 28 of 
identified TLs (33%). PC was histopathologically verified in 56 of 
86 TLs (65%) with a maximum median diameter of 15 mm (range 
2 to 40). Of these 56 histopathological PC positive TLs CEUS 
revealed suspicious perfusion patterns in 52 (93%). 
Hypoperfusion and hyperperfusion were identified in 27 (48%) 
and in 25 TLs (45%), respectively. Only 4 normoperfused TLs 
(7%) on CEUS showed histopathologically malignant tissue. 
When comparing normoperfused TLs vs suspiciously perfused 
(hypoperfused or hyperperfused) TLs to detect 
histopathologically proven cancer, statistical analysis revealed 
statistically significant differences (p≤0.001 ). Using transrectal 
SE alone showed a false-positive result in 30 of 86 TLs (35%). 
Adding CEUS to RTE decreased the false-positive result to 6 of 
58 TLs (10%). In other words, if the transrectal SE positive TL 
showed a suspicious perfusion pattern, the likelihood of 
correctly detecting histopathological PC was 90%. Due to the 
finding that cancer more likely showed abnormal perfusion 
patterns than benign lesions on transrectal SE, we investigated 
whether the Gleason score in the defined area might correlate 
with hypoperfusion or hyperperfusion. In each group of TLs with 
suspicious perfusion patterns Gleason 4 was predominant. 
However, the predominant Gleason score in the TL did not 
significantly correlate with the perfusion pattern during CEUS 
(p≤  0.12). Histopathological examination of the 4 TLs considered 
normoperfused revealed Gleason 3 in 2 (50%) and Gleason 4 in 2 
(50%). The maximum diameter of these lesions was 2, 3, 17 and 
26 mm, respectively. 
The detection rate of our standard prostate biopsy TRUS guided 
























To our knowledge this is the second prospective study 
combining transrectal SE and CEUS in a multiparametric imaging 
approach to investigate PC in patients before RP. In the defined 
TL transrectal SE alone identified histopathological PC 
infiltration with a positive predictive value of 65%. Adding CEUS 
to visualize microvessel perfusion patterns improved the 
positive predictive value to correctly identify cancer to 90%. 
Based on the low sensitivity and accuracy of gray scale 
ultrasound alone, various imaging techniques have been 
introduced to optimize PC visualization. Since its first 
introduction in 1991 by Ophir et al, transrectal SE has been 
established at various urological centers of excellence to provide 
an additional tool to improve PC detection [42]. Several groups 
have investigated the accuracy of transrectal SE correlated with 
biopsy results to detect PC [49]. Despite promising results in 
regard to using this imaging technique with biopsy results, 
sensitivity and specificity did not attain levels that would enable 
safe visualization of lesions in the gland preoperatively. Thus, to 
determine the true sensitivity or specificity of transrectal SE a 
correlation with thin sectioned whole mount prostatectomy 
specimens is obligatory [41]. Studies investigating a correlation 
with whole mount slides showed variable 57% to 100% 
sensitivity [50]. Salomon et al investigated 109 patients and 
reported overall 75.4% sensitivity and 76.7% specificity for 
cancer detection [44]. Tsutsumi et al reported 57% to 94% 
variable sensitivity depending on lesion anatomical location 
according to the sextant scheme used in that study [51]. They 
postulated higher sensitivity in the ventral than in the dorsal 
parts of the gland. Other studies revealed better transrectal SE 
accuracy for the apex of the prostate compared to the base [52]. 
In an earlier study in 229 patients we evaluated the staging 
ability of transrectal SE [43]. Sensitivity was 51% and specificity 
was 72%. In addition, we identified extracapsular extension of 
PC with 38% sensitivity and 96% specificity. 
In addition to the limitation of a known learning curve to apply 
transrectal SE, this technique is associated with a high number 
of false-positive results, especially in areas of former prostatitis, 
which can lead to the fibrosis of benign prostate hyperplasia 
(49,53,54). Due to the limitations of transrectal SE alone we, as 
already did Brock et al [55], hypothesized that adding CEUS 
might improve the distinction of benign from malignant areas by 
visualizing perfusion patterns resulting from cancer impacted 
changes to the microvessel architecture. Since the initial report 
in 1993 of increased capillary density of prostatic carcinoma by 
Bigler et al [45] several groups have found that microvessel 
density is significantly higher in cancer than in benign tissue [56, 
57]. Sedelaar et al noted that CEUS enhanced areas had 1.93 
times higher microvessel density than nonenhanced 
areas in the prostatectomy specimen [58]. Matsumoto et al 
evaluated 50 patients before RP using a bolus injection of 
contrast agent [59]. They identified at least 1 tumor focus in 
62% of cases when counting the areas of increased contrast 
enhancement, and reported 30.8% sensitivity for CEUS. Halpern 
et al observed an improved sensitivity of 42% in 12 patients with 
biopsy proven PC [60]. Sano et al expanded the definition of 
CEUS malignancy according to the theory that various 
histopathological cancer types can coexist in a single patient 
[61]. Evaluation of 13 patients before RP revealed variable 
behavior of contrast enhancement. Consistent with the findings 
of Sano et al, we observed suspicious perfusion (hypoperfusion 
or hyperperfusion) of cancer. In cases of suspicious 
hypoperfusion or hyperperfusion the examined TL showed 
histopathological PC in 52 of 58 cases (89.6%). Using a 
multiparametric targeted biopsy approach Aigner et al observed 
that the overall 59.4% PC detection rate (70 of 133 cases) was 
superior to that of a systematic approach [62]. Combining 
transrectal SE and CEUS in our study significantly decreased the 
false-positive results of transrectal SE alone from 34.9% to 
10.3% and thereby improved the positive predictive value to 
89.7% to correctly identify histopathologically confirmed PC in 
defined TLs. Although there was a trend toward higher Gleason 
patterns in hyperperfused TLs in our study, statistical analysis 
did not attain significance to assign a Gleason score to a 
hypoperfused or hyperperfused imaging pattern. In addition to 
the limitations associated with a pilot study, hematoxylin and 
eosin stained whole mount slides were histopathologically 
evaluated by a dedicated uropathologist but microvessel density 
using immunohistological markers was not assessed. The 
segmentation into 12 prostate sectors applied in our study 
carries the risk of inaccurate documentation of PC. To date no 
standard consensus for ultrasound PC evaluation has been 
recommended. However, using a segmentation system with 
additional sectors (e.g. recommendations for magnetic 
resonance imaging of an optimal requirement of 27 regions) 
might enhance reporting accuracy [63]. Evaluation of transrectal 
SE combined with CEUS in our exploratory study was limited to 
defined TLs according to the design of our protocol because 
screening the whole prostate using CEUS is associated with the 
difficulty of accurately visualizing the whole gland in a short 
time. Contrast enhanced perfusion to detect suspicious areas 
depends on the time after the contrast agent is administered 
and Aigner et al observed optimal detection in the first 15 to 20 
seconds after injection [64]. Consistent with their findings, we 
noted the best visualization of suspicious contrast enhancement 
patterns within the first 20 seconds after infusion. Repeat 
intravenous injections of contrast agent or specific techniques 
that enable reperfusion, such as the replenishment technique, 
might improve the evaluation of multiple cross sections [61]. 
The evaluation of CEUS behavior might be affected by patient 
position, which could have an influence on prostatic blood flow 
[65]. Therefore, the supine position may affect the outcome of 
CEUS in future examinations. The results of our study highlight 
the possible use of combining various imaging techniques, such 
as gray scale ultrasound, transrectal SE and perfusion imaging, in 
a multiparametric approach to improve and optimize prostate 
cancer detection and visualization. Nevertheless, this integrated 
approach, despite demonstrated an overall detection rate 
higher than our standard biopsy detection rate, was too 
expensive, and required an intricate diagnostic process.  
 
Conclusions 
In our study we demonstrated that adding the dimension of 
perfusion imaging using a combined approach of transrectal SE 
and CEUS resulted in a significant decrease in false-positive 
results and improved the positive predictive value of correctly 
identifying histopathological cancer, but, the cost of the 
imaging, the increase in the time and in the complexity of the 
diagnostic process, did not support the availment of this 
method, especially if compared with the our detection rate with 
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